Dexcom names CFO Jereme Sylvain chief operating officer
DexCom expanded CFO Jereme Sylvain’s role to also serve as COO, with updated compensation terms reflecting broader operational responsibility.
Rhea-AI Filing Summary
DexCom, Inc. (DXCM) reported that its Board of Directors appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role of Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. The move consolidates oversight of global operations, quality and finance under Mr. Sylvain.
Under an offer letter dated September 11, 2026, Mr. Sylvain will receive an annual base salary of $767,000 and an annual target bonus opportunity equal to 75% of base salary, and remains eligible for equity awards and participation in Dexcom’s existing executive severance and benefit plans.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Effective date of new role: September 14, 2026
Annual base salary: $767,000
Target bonus opportunity: 75% of base salary
+4 more
7 metrics
Effective date of new role
September 14, 2026
Date Jereme Sylvain’s EVP, COO and CFO role becomes effective
Annual base salary
$767,000
Base salary for Jereme Sylvain under the new Offer Letter
Target bonus opportunity
75% of base salary
Annual target bonus percentage for Jereme Sylvain
Board appointment date
September 10, 2026
Date the Board approved Jereme Sylvain’s expanded role
Offer Letter date
September 11, 2026
Date Jereme Sylvain entered into the new Offer Letter
Year joined DexCom
2018
Year Jereme Sylvain joined DexCom
Year became CFO
2021
Year Jereme Sylvain became Executive Vice President and Chief Financial Officer
Key Terms
Regulation FD, Amended and Restated 2015 Equity Incentive Plan, Amended and Restated Severance & Change in Control Plan, glucose biosensing, +1 more
5 terms
Regulation FD regulatory
"ITEM 7.01. REGULATION FD DISCLOSURE."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Amended and Restated 2015 Equity Incentive Plan financial
"eligible to receive annual equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan"
Amended and Restated Severance & Change in Control Plan financial
"to participate in the Company’s Amended and Restated Severance & Change in Control Plan"
glucose biosensing medical
"DexCom, Inc., the global leader in glucose biosensing, today announced"
Glucose biosensing is the use of a biological or chemical sensor to detect and measure blood sugar levels, typically through a small device or patch that reads body fluids and converts that signal into a readable number. Investors care because these sensors can drive steady revenue from devices and consumables, change how chronic diseases are managed, and face regulatory and adoption hurdles similar to launching a new consumer gadget — think of it as a reliable meter that tells you how your body’s fuel is behaving.
Inline XBRL technical
"Cover Page Interactive Data File (formatted as Inline XBRL)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive leadership change did DXCM announce on September 14, 2026?
DexCom announced that Jereme Sylvain, previously Executive Vice President and Chief Financial Officer, was promoted to Executive Vice President, Chief Operating Officer and Chief Financial Officer, with the expanded role effective September 14, 2026.
What is Jereme Sylvain’s new compensation structure at DexCom (DXCM)?
Under a new offer letter, Jereme Sylvain will receive an annual base salary of $767,000 and an annual target bonus opportunity equal to 75% of his base salary, in addition to continued eligibility for annual equity awards and participation in DexCom’s executive benefit plans.
When did DexCom’s Board approve Jereme Sylvain’s expanded role?
DexCom’s Board of Directors appointed Jereme Sylvain to the role of Executive Vice President, Chief Operating Officer and Chief Financial Officer on September 10, 2026, with the appointment effective September 14, 2026.
Is Jereme Sylvain still eligible for equity incentives and severance plans at DexCom (DXCM)?
Yes. DexCom indicates that Jereme Sylvain remains eligible for annual equity awards under the Amended and Restated 2015 Equity Incentive Plan and to participate in the company’s Amended and Restated Severance & Change in Control Plan as an executive officer.
How long has Jereme Sylvain been with DexCom (DXCM)?
DexCom notes that Jereme Sylvain joined the company in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021 before assuming the additional Chief Operating Officer responsibilities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 10, 2026
(Exact Name of the Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
(858 ) 200-0200
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||||||||||
Emerging growth company | ||||||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||||||||
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.
In connection with Mr. Sylvain’s promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the “Offer Letter”) providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan, to participate in the Company’s Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.
Biographical and other information for Mr. Sylvain is set forth in Dexcom’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2026, and is incorporated herein by reference. There is no arrangement or understanding between Mr. Sylvain and any other persons pursuant to which such person was selected as an officer. There are no family relationships among any of Dexcom’s directors or executive officers and Mr. Sylvain, and Mr. Sylvain does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the Offer Letter, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
ITEM 7.01. REGULATION FD DISCLOSURE.
On September 14, 2026, Dexcom announced the promotion of Mr. Sylvain in a press release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| Number | Description | |||||||
| 99.1 | Press release dated September 14, 2026 | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DEXCOM, INC. | ||||||||
| By: | /s/ JEREME SYLVAIN Jereme Sylvain Executive Vice President, Chief Operating Officer and Chief Financial Officer | |||||||
Date: | September 14, 2026 | |||||||
Exhibit 99.1
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
SAN DIEGO - (BUSINESS WIRE- September 14, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcom’s global operations and quality teams, driving greater alignment, speed, and accountability across the company as it executes on its vision for growth and commitment to operational excellence.
Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. Throughout his tenure at Dexcom, Mr. Sylvain has built a strong finance leadership team and guided the company’s journey of growth and margin expansion. He has also demonstrated the ability to align and execute cross-functionally, bringing the combination of strategic judgment, operational discipline, and commitment to customers that are key for Dexcom’s next phase of growth and scale.
“Jereme is an exceptional leader and a valued strategic partner across Dexcom,” said Jake Leach, President and CEO. “His deep understanding of our business, operational discipline and customer focus make him the right leader for this expanded role. I am confident that Jereme will help us scale more effectively as we advance our goal to empower millions more people to take control of health.”
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit Dexcom.com.
Category: IR
Media Contact
Nadia Conard
mediarelations@dexcom.com
Investor Contact
Sean Christensen
investor-relations@dexcom.com